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I congratulate the authors again on
a most thought-provoking study. I look
forward to their feedback about these con-
siderations.
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Philadelphia, PA 19104-4283
Financial support: Department of Anesthesiology
and Critical Care, Hospital of the University of
Pennsylvania.
References
1. Murthy SC, Arroliga AC, Walts PA, Feng J,
Yared JP, Lytle B, et al. Ventilatory depen-
dence after cardiovascular surgery. J Thorac
Cardiovasc Surg. 2007;134:484-90.
2. Sedrakyan A, Wu A, Sedrakyan G, Diener-
West M, Tranquilli M, Elefteriades J. Aproti-
nin use in thoracic aortic surgery: safety and
outcomes. J Thorac Cardiovasc Surg. 2006;
132:909-17.
3. Brown JR, Birkmeyer NJO, O’Connor GT.
Meta-analysis comparing the effectiveness
and adverse outcomes of antifibrinolytic
agents in cardiac surgery. Circulation. 2007;
115:2801-13.
doi:10.1016/j.jtcvs.2007.09.056
Reply to the Editor:
We appreciate the comments provided by Dr
Augoustides in regard to our recent article
‘‘Ventilatory Dependency After Cardiovas-
cular Surgery.’’ Our article attempts to de-
fine the risks for ventilator dependency and
determine the outcomes of patients who de-
velop this problem after their index cardio-
vascular surgery. Two inquiries were made
(as points [a] and [c] are closely related).
We were surprised ourselves to find that
there has been a continuing trend toward
a lower prevalence of ventilator dependency
at our institute. A declining trend was noted
in previous studies from our institute pub-
lished several years before. That this trend
has continued through the current study
has both thrilled and perplexed us. It was im-
possible for us to determine which quantifi-
able variables might be responsible for this
trend because of a variety of confounding
factors, not the least of which is time itself.
What is even more interesting is that this
phenomenon has occurred in the setting of
increasing complexity and acuity of illness.
It is our suspicion that several coincident
changes might be responsible. There has
been a steady improvement in myocardial
protection over the years and a progressive
increase of intraoperative echocardiography
use; these factors likely promote more rapid
myocardial recovery. Less narcotics are be-
ing given intraoperatively, and this may fa-
cilitate earlier separation from mechanical
ventilatory support. In addition, there has
been a noticeable increase in intensivist
staffing, such that there is seemingly more
planning and continuity of care in the inten-
sive care unit, which again, might favorably
affect weaning.
Second, aprotinin is used sparingly at
our institution (in ,1% of patients). This
is, in part, secondary to cost, but also for
concerns regarding thrombotic complica-
tion and renal dysfunction, all without
clearly demonstrable benefit. There are 2
populations for whom we do use aprotinin
on more occasions: patients with ventricu-
lar-assist devices and patients undergoing
a second cardiac transplant. These groups
were excluded from our study.
Sudish C. Murthy, MD, PhD
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To the Editor:
We read with interest the article of Totaro
and Argano.1 We have, however, several
concerns with regard to the validity of the
results and conclusions presented in this
article. First, the title of the article, ‘‘Pa-
tient–Prosthesis Mismatch after Mitral
Valve Replacement: Myth or Reality?’’ is
inappropriate. Mitral prosthesis–patient
mismatch (PPM) is equivalent to a residual
mitral stenosis, related to the fact that most
prosthetic valves have a hemodynamic per-
formance, and thus a valve effective orifice
area (EOA), that is inferior to that of the nor-
mal native valve. Thus concluding that PPM
is a myth would be equivalent to saying that
mitral stenosis (or aortic stenosis for aortic
PPM) does not exist, and that this is a benign
phenomenon, which is of course not the
case. In this regard, several studies have
demonstrated that PPM is a frequent hemo-
dynamic phenomenon after mitral or aortic
valve replacement.2-5 The important ques-
tion is rather to determine the impact of
PPM on the hemodynamic, functional, andascular Surgery c February 2008clinical outcomes, and at which degree of
severity and in which categories of patients
this impact of PPM becomes statistically
significant and clinically relevant. Unfortu-
nately, the data provided by Totaro and
Argano1 do not permit an answer to these
important questions.
There are serious concerns about the val-
idity of the Doppler echocardiographic data,
and especially of those of the valve EOA.
This is a crucial aspect, because the identifi-
cation and quantification of PPM are based
on these data. First, it is intriguing to see
that the EOAs measured in vivo by Doppler
echocardiography, especially for the 25- and
27-mm valves, were larger than the EOAs
measured in vitro by the manufacturer. A re-
cent study has indeed demonstrated that, as
opposed to the observation in this study, the
in vitro EOAs provided by the manufacturer
grossly overestimate the in vivo EOAs and
are thus not valid for prediction of PPM.6
Totaro and Argano also used the label pros-
thesis size as a surrogate for PPM, whereas
previous studies have shown that this
parameter is not valid for identification of
PPM and prediction of its hemodynamic
and clinical consequences.3,6,7
Moreover, the huge variability in the
EOA measurements for a given prosthesis
size (from 1.0 to 4.9 cm2 for the 29-mm pros-
theses!), the complete absence of correlation
between the EOA and the transprosthetic gra-
dient, and the recording of high transpros-
thetic gradients (.15 mm Hg) in several
patients despite the calculation of large
EOAs and indexed EOAs (see Figure 3 of
the article1) further support the concerns
regarding the validity of the EOA measure-
ments and thus the identification of PPM.
The presence of gradients greater than 15
mm Hg in the mitral position definitely
cannot be considered as ‘‘favorable hemody-
namics,’’ as concluded by Totaro and
Argano.1 In fine, these observations suggest
that a large proportion of the patients in-
cluded in this series were misclassified with
respect to the presence or absence of PPM.
Totaro and Argano only measured the
valve hemodynamics and systolic pulmo-
nary arterial pressure at predischarge exam-
ination or at 30 days. It is well known that
the measurements of valve EOA, transvalv-
ular gradients, and pulmonary pressure in
the early postoperative period are often
unreliable because of the poor acoustic win-
dow, hyperdynamic state, or flow accelera-
tion in the left ventricular outflow tract.
Reply to the Editor:
We thank Pibarot and coauthors for their
comments regarding our article.1 It is surely
a privilege that such distinguished colleagues
take an interest in our study. Nevertheless, we
found some of the comments inappropriate.
First, as far as the title was concerned, it
was obviously provocative and was chosen
just to underline an important matter related
to this issue. As Pibarot and coauthors
stressed in their comment, patient–prosthe-
sis mismatch (PPM) is a hemodynamic phe-
nomenon and therefore should be diagnosed
on the basis of hemodynamic parameters
related to a specific patient. This is the key
point related to PPM after mitral valve
replacement. In other words, to evaluate
clearly the impact of PPM on functional
and clinical outcomes, we have to be sure
that we are comparing patients with PPM
to patients without PPM.
As we clearly stated, this was the main
objective of our study, which was indeed fo-
cused on the identification of patients with
real PPM and on the evaluation of accuracy
of prediction and diagnosis of PPM with
data not obtained in vivo postoperatively
and therefore not related to a specific patient.
In their comments, Pibarot and coauthors
express serious concerns about the validity
of our Doppler echocardiographic data,
especially those related to effective orifice
area (EOA). We would stress that the meth-
odology we used (continuity equation
method) was validated for assessing mitral
valve bioprosthesis by their own group2;
they also confirmed the good correlation be-
tween the mean in vitro and in vivo areas for
mitral prostheses. In our hands in vivo post-
operative measured EOA was indeed larger
than the EOA measured in vitro by the
manufacturer. We stressed such interesting
results in our discussion, and we also stressed
that these findings were surely unexpected on
the basis of what has clearly been demon-
strated for aortic prostheses. We do believe,
however, that our results deserve a further
analysis rather than mere criticism. It is nota-
ble that, despite few data on postoperative
hemodynamic performance after mitral valve
replacement being available, Firstenberg and
colleagues3 in 2001 reported echocardio-
graphic data consistent with our findings.
They specifically evaluated postoperative in
vivo hemodynamic performances of the
mitral Carpentier Edwards Perimount valve,
and the postoperative in vivo EOAs they
reported were consistent with our data. We
do stress that they also reported a discrete
variability (expressed in terms of SD), once
more similar to our own findings. We are still
collecting and analyzing our data for better
evaluation of the reason for such variability,
but we do believe that it is related to the fact
that the postoperative prosthetic valve in
vivo EOA depends on other physiopatho-
logic parameters than simple prosthesis
size. Different sensitivities of mitral valve he-
modynamics to chronotropic conditions,
which may vary extensively from one patient
to another was furthermore previously noted
by Pibarot and Dumesnil4 themselves in their
Journal editorial of June 2007. Further
studies addressing postoperative in vivo
hemodynamic parameters could be more
helpful in better understanding such variabil-
ity, rather than criticizing our results and
doubting their validity. In contrast to what
they stated in their comments, we did not
mention at all the ‘‘the complete absence of
correlation between the EOA and the trans-
prosthetic gradient’’ (which was, however,
previously shown by Firstenberg and co-
workers3), but rather the absence of correla-
tion between increased prosthesis size and
improved postoperative hemodynamic per-
formance. A similar concept was also previ-
ously presented by Badano and associates5
and therefore is not a unique finding of our
study.
We do not agree at all with Pibarot and
coauthors’ concerns about the ‘‘large pro-
portion of the patients included in this series
Letters to the EditorMoreover, the adverse effect of PPM on pul-
monary arterial pressure may in large part
occur in the long term. Thus the early post-
operative pulmonary arterial pressure is ob-
viously not an appropriate and reliable end
point for adequate assessment of the effects
of PPM. As opposed to the results of this
study, three recent previous studies have re-
ported that PPM is associated with a higher
incidence of persistent pulmonary hyperten-
sion after mitral valve replacement.2-4
The number of patients is far too small
and the follow-up too short to draw any
meaningful conclusion with regard to the
impact of PPM on operative and late mortal-
ities, on the persistence of pulmonary hyper-
tension, or on any other clinical outcomes.
Importantly, there is a major discrepancy
between the data reported in this small series
of patients with very short follow-up and the
data reported by two independent groups of
investigators in much larger series of pa-
tients (.800) with more than 10 years of
follow-up.3,4 These larger studies concluded
that mitral PPM, and especially severe PPM,
is an independent predictor of the persis-
tence of pulmonary hypertension, the occur-
rence of congestive heart failure, and late
mortality.
In light of the important limitations of
this study and of the results of previous stud-
ies,2-4 the results and conclusions of the
article of Totaro and Argano1 cannot be ac-
cepted at face value. We believe that among
several prosthesis models that are equivalent
in terms of durability and thromboresistance
the surgeon should logically select the one
with the largest possible EOA in a given an-
nulus size to minimize the risk of PPM and
associated complications after mitral valve
replacement.
Philippe Pibarot, DVM, PhD, FACC, FAHA
Julien Magne, MSc
Jean G. Dumesnil, MD, FRCPC, FACC
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